CTMX has been granted a new patent
Dec 11, 2024, 11:36 PM
-16.71%
What does CTMX do
CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.
CTMX filed a patent for "activatable antibodies that bind epidermal growth factor receptor and methods of use thereof" on Tue, December 26, 2023. The patent was officially published on Thu, December 5, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.